NCT05155839Unknown1 期
An Open-label, Multicenter, First-in-human, Phase I Dose-escalation and Expansion Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of MRG001 in Patients With CD20-positive Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 108
- 试验地点
- 12
- 主要终点
- Adverse Events (AEs)
研究概览
简要总结
This study consists of two parts. Phase Ia is a dose escalation study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG001. Phase Ib is a dose expansion study to assess the preliminary efficacy of MRG001 in patients with CD20-positive relapsed or refractory B-cell NHL at the confirmed RP2D. The safety, tolerability, pharmacokinetic (PK) and immunogenicity of MRG001 will be evaluated in both parts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participates in the clinical study; Fully understands and informed of this study, and provides written informed consent; Willing to follow and have the ability to complete all trial procedures.
- •Aged 18 to 80 (including 18 and 80), male or female.
- •Patients with histopathologically confirmed relapsed/refractory B-cell non-Hodgkin lymphoma.
- •Relapsed or refractory disease after standard of care treatment with anti-CD20 antibodies.
- •Patients must have at least one measurable lesion without prior local therapy according to Lugano 2014 criteria.
- •The score of ECOG for performance status is 0 or
- •Patients without severe hematopoietic, liver and kidney dysfunction.
- •Expected survival time ≥ 3 months.
- •Prior anti-tumor treatment-related AEs (NCI CTCAE v5.0 Criteria) have recovered to ≤ Grade
- •Negative blood pregnancy test for women of childbearing potential within 7 days prior to the first dose of study drug. Patients of childbearing potential should agree to use effective contraception from signing the ICF until 3 months after the last dose of study drug.
- •The score of left ventricular ejection fraction (LVEF) is > 50%.
排除标准
- •Applicable to Phase Ia: positive hepatitis B surface antigen (HBsAg), or negative HBsAg with a peripheral blood hepatitis B virus DNA copy number greater than the upper limit of normal; positive hepatitis C virus (HCV) antibody and positive HCV RNA at screening. Patients with a history of clinically significant non-viral hepatitis and cirrhosis. Applicable to Phase Ib: positive hepatitis B surface antigen (HBsAg) and/or positive hepatitis B core antibody (HBcAb) at screening, and peripheral blood hepatitis B virus DNA copy number greater than the upper limit of normal; positive hepatitis C virus (HCV) antibody and positive HCV RNA. Patients with a history of clinically significant non-viral hepatitis and cirrhosis (decompensated cirrhosis Child-Pugh class B, C).
- •Positive human immunodeficiency virus (HIV) antibody.
- •Any active infection requiring systemic therapy occurred within 2 weeks before enrollment.
- •Suspected or confirmed central nervous system invasion of NHL.
- •Allergic constitution or known hypersensitivity to rituximab or other anti-CD20 monoclonal antibodies and their components, or hypersensitivity to any component of MRG
- •Patients with uncontrolled or significant cardiovascular disease.
- •History of severe pulmonary disease.
- •Received CAR-T therapy within 3 months before enrollment.
- •Received blood transfusion within 28days before enrollment, or receiced erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and other drugs that may affect hemogram within 14 days before enrollment.
- •Current use of potent CYP3A4 inhibitors or inducers.
- •History of allogeneic stem cell transplantation or organ transplantation, or have received autologous stem cell transplantation within 3 months prior to screening, or plan to undergo stem cell transplantation.
- •Suffered from other malignancies within the last 5 years.
- •Major surgery within 6 weeks prior to enrollment or planned major surgery within the first 12 weeks after receiving study drug.
- •Patients who are receiving any approved or investigational anti-tumor treatment with antibody/fusion protein/ADC drugs, radiotherapy, chemotherapy, Chinese patent medicine or Chinese herbal medicine within 28 days before enrollment; or have participated in any approved or investigational small molecule targeted therapy within 28 days before enrollment or within 5 half-lives (whichever is shorter).
- •Received any vaccine within 28 days prior to enrollment or will receive any vaccine within 6 months after the last dose of study drug.
- •Requires treatment with glucocorticoids or other immunosuppressive agents for a certain condition within 14 days prior to enrollment.
- •An acute oncolytic reaction may occur at the discretion of the investigator.
- •Inability to complete protocol-specified study visits and study drug administration.
- •Women during pregnancy or lactation; men and women of childbearing potential who are unwilling to take prescribed appropriate contraceptive measures.
- •Other conditions inappropriate for participation in this clinical trial at the discretion of the investigator.
- •Malignant lymphoma with pathological transformation.
- •High-grade B-cell lymphoma.
- •Patient's Body Mass Index ≤ 17 kg/m
- •Patients with underlying medical conditions that, in the judgment of the investigator, might increase the risk of receiving study drug or might affect the safety assessment of the study drug.
研究组 & 干预措施
MRG001
Experimental
All patients in Phase Ia (dose escalation) and Phase Ib (dose expansion) will be administrated MRG001 on Day 1 of every 3 weeks (21-day cycle).
干预措施: MRG001 (Drug)
结局指标
主要结局
Adverse Events (AEs)
时间窗: Baseline to 90 days after the last dose of study treatment.
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.
Maximum Tolerated Dose (MTD)
时间窗: DLT will be evaluated during the first treatment cycle (Day 1-21).
The highest dose confirmed wherein ≤ 1/6 of patients in a treatment cohort experiences a dose-limiting toxicity (DLT) within 21 days after the first dose of study treatment.
Recommended Phase II Dose (RP2D)
时间窗: Baseline to study completion (up to 15 months).
The dose level of MRG001 recommended for further phase II clinical studies.
次要结局
- Progression Free Survival (PFS)(Baseline to study completion (up to 15 months))
- Immunogenicity(Baseline to 30 days after the last dose of study treatment)
- Objective Response Rate (ORR)(Baseline to study completion (up to 15 months))
- Overall Survival (OS)(Baseline to study completion (up to 15 months))
- PK parameter: Concentration-time curve(Baseline to 90 days after the last dose of study treatment.)
- Duration of Response (DoR)(Baseline to study completion (up to 15 months))
- Disease Control Rate (DCR)(Baseline to study completion (up to 15 months))
研究者
研究点 (12)
Loading locations...
相似试验
Unknown
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid TumorsReceptor, ErbB-2NCT05145179Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.162
终止
1 期
JSKN033 in Patients With Advanced or Metastatic Solid Malignant TumorsAdvanced Solid TumorNCT06226766Jiangsu Alphamab Biopharmaceuticals Co., Ltd11
招募中
1 期
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid TumorsLocally Advanced/Metastatic Solid TumorsNCT06414460InSilico Medicine Hong Kong Limited146
招募中
1 期
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.Neuroendocrine CarcinomaNCT06440057Suzhou Zelgen Biopharmaceuticals Co.,Ltd78
招募中
1 期
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerNeuroendocrine CancerSmall Cell Lung CancerNCT06283719Suzhou Zelgen Biopharmaceuticals Co.,Ltd265